Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: software salesperson who wrote (51997)	12/1/2022 3:02:47 PM
From: A.J. Mullen	2 Recommendations Recommended By Lance Bredvold OldAIMGuy Read Replies (1) \| Respond to of 52153

Thanks for that. The trial results suggest lecanemab delays the onset of symptoms. There's no evidence of reversal and the author adds the effect was only significant at 18 months - not at 12. He sees the glass as half-empty. It looks like the delay is cumulative. The drug might make a substantial difference to a relatively young person newly diagnosed. The trial included people as young as 50, with many years left. The increased number of adverse effects in the drug arm of the trial is a concern. That's something for the FDA to chew on. At last, a drug has come out of treating amyloid plaques (or, in this case, a precursor). The Amyloid hypothesis was looking exhausted. Lecanemab will breath more life into it.